UNDERSTAND YOUR PANEL OPTIONS
Drug Test Panel Guide
Drug abbreviations, familiar medication examples, and practical screening limitations—plus approximate urine detection windows—all in one easy-to-read reference.
Bulk and Wholesale Pricing • Nationwide Shipping
This is a selected reference of common and expanded drugs-of-abuse (DOA) targets, not an exhaustive worldwide catalog or a list of products currently stocked by MyDrugTestCups. Examples identify related drugs, not a verified detection claim for a particular cup. Consult each product’s manufacturer instructions, specimen requirements, target analytes, and cutoffs.
These ranges describe detection in urine after last use, not duration of effects, impairment, or complete removal from the body. They are general laboratory references, not performance guarantees for a rapid cup. Dose, frequency, formulation, kidney/liver function, urine concentration, assay target, and cutoff can change the window. Long-acting injections require separate interpretation. Oral-fluid, blood, hair, and substance tests use different rules.
Common drug panels
| Panel | Drug or target | Common examples | Approximate urine detection after last use | What to know |
|---|---|---|---|---|
| AMP | Amphetamines | Adderall; Dexedrine; Vyvanse | 1–7 days [source] | Vyvanse is converted to dextroamphetamine. Methylphenidate is not an amphetamine. |
| BAR / BARB | Barbiturates | Phenobarbital; butalbital (Fioricet, Fiorinal); pentobarbital; secobarbital | Drug-dependent; phenobarbital 1–16 days, butalbital 1–18 days [source] | Detection varies by compound and assay. |
| BUP | Buprenorphine | Suboxone; Zubsolv; Subutex; Sublocade; Brixadi | 1–10 days for many formulations; long-acting injections can remain detectable much longer. Do not apply this range to depot injections. [source] | Buprenorphine-containing products; this panel does not identify the brand or detect naloxone specifically. |
| BZO / BZD | Benzodiazepines | Diazepam (Valium); temazepam (Restoril); oxazepam; chlordiazepoxide (Librium) | Often days; up to 6 weeks with heavy use of long-acting drugs. Sensitivity varies. [source] | Many screens have poor sensitivity to alprazolam (Xanax), lorazepam (Ativan), and clonazepam (Klonopin). Verify the assay. |
| COC | Cocaine | Powder cocaine; crack cocaine | Usually 2–4 days; 10–22 days reported with heavy use [source] | Urine assays generally target benzoylecgonine, a cocaine metabolite. |
| MET / MAMP | Methamphetamine | Meth; crystal meth; ice; Desoxyn | 1–4 days [source] | A screening result cannot establish the source. |
| MDMA / XTC | MDMA | Ecstasy; Molly | 1–3 days [source] | Street products may contain substances other than MDMA. |
| MOR / MOP / OPI | Morphine / opiate screening | Morphine (MS Contin); codeine (Tylenol with Codeine); heroin-derived morphine metabolites | Morphine and codeine: 1–3 days; heroin-specific 6-MAM has a much shorter window [source] | These labels vary by product. A morphine result does not specifically identify heroin. Do not assume fentanyl or all opioids are detected. |
| MTD | Methadone | Methadone; Methadose; Dolophine | 1–14 days [source] | Distinct from the EDDP metabolite panel. |
| OXY | Oxycodone | OxyContin; Percocet; Roxicodone; Xtampza ER | 1–3 days [source] | Examples contain oxycodone; brand cannot be identified. |
| PCP | Phencyclidine | PCP; angel dust | 1–7 days; repeated use can extend detection [source] | Confirm preliminary positive results. |
| THC | Cannabis | Marijuana; hashish; THC-containing edibles, vapes, and concentrates | About 1–3 days with infrequent use; chronic use may remain detectable 30 days or longer [source] | Urine screening generally targets a THC metabolite; it does not establish current impairment. |
Expanded & specialty panels
| Panel | Drug or target | Common examples | Approximate urine detection after last use | What to know |
|---|---|---|---|---|
| FEN / FTY / FNT | Fentanyl | Fentanyl; Duragesic; illicitly manufactured fentanyl | 1–7 days; repeated exposure and metabolite testing may extend detection [source] | Coverage of analogs varies. |
| 6-MAM / 6-AM | Heroin metabolite | 6-monoacetylmorphine | Brief window, often about 6 hours [source] | A specific heroin metabolite; different from a general morphine screen. |
| EDDP | Methadone metabolite | EDDP | Assay-dependent; ask the testing laboratory for its EDDP-specific window | A breakdown product of methadone; different from MTD. |
| HYD / HYC | Hydrocodone | Norco; Vicodin; Lortab; Hysingla ER | 1–3 days [source] | Requires appropriate assay coverage. |
| HMO / HYMO | Hydromorphone | Hydromorphone; Dilaudid | 1–4 days [source] | Do not assume a general opiate screen detects it reliably. |
| TRA / TML | Tramadol | Tramadol; Ultram; Ultracet | 1–4 days [source] | A dedicated target; not automatically covered by opiate screening. |
| KET | Ketamine | Ketamine; Ketalar; Special K | Approximately 1–3 days; assay target and repeated use can extend detection [source] | Verify esketamine coverage separately. |
| KRA / MIT | Kratom-associated alkaloids | Kratom leaf, powder, capsules, and extracts | Variable; no single reliable window for all kratom products and rapid tests | Often targets mitragynine. Do not assume coverage of all 7-hydroxymitragynine products. |
| GAB | Gabapentin | Neurontin; Gralise; generic gabapentin | 1–2 days [source] | Separate from pregabalin. |
| PGB / PREG | Pregabalin | Lyrica; generic pregabalin | 1–2 days [source] | Separate from gabapentin. |
| K2 / SPICE | Selected synthetic cannabinoids | Certain compounds sold as K2 or Spice | Compound- and assay-specific; no universal window | No single strip detects all synthetic cannabinoids. |
| TCA | Tricyclic antidepressants | Amitriptyline; nortriptyline (Pamelor); imipramine (Tofranil); doxepin | Drug- and assay-specific; verify the medication and test with the laboratory | Cross-reactivity and detection vary. |
| PPX | Propoxyphene | Propoxyphene; older products Darvon and Darvocet | Consult the specific assay documentation; no general range assigned here | Historical medication examples, not a statement of current availability. |
| ZOL | Zolpidem | Ambien; Edluar; Intermezzo | 1–3 days [source] | Not automatically covered by a benzodiazepine screen. |
| XYL | Xylazine | Xylazine; tranq | Rapid-strip window is not established here; laboratory research estimates cannot be applied directly to a cup | Verify whether the product is for urine or substance testing. |
| LSD | Lysergic acid diethylamide | LSD; acid | Assay- and metabolite-dependent; confirm with the laboratory | Specialty assay availability and specimen requirements vary. |
Specimen-validity checks
These assess specimen characteristics. They do not add drug classes to a panel count.
Choose the right test for your program
Treatment centers, sober living programs, employers, corrections programs, healthcare practices, and testing providers have different needs. Match the product’s intended-use labeling and specimen type to your program. Do not assume a rapid cup meets DOT testing requirements.
Urine, oral-fluid, hair, and substance-testing products are different. Never use a urine test on powders or other materials unless the manufacturer explicitly permits that use.
Reading the label
Abbreviations vary across manufacturers. Labels such as ACM and K3 require the specific manufacturer’s definition. A panel count alone does not identify which drugs are included.
Understanding results
Drug concentration, timing, metabolism, specimen dilution, cutoff, and assay sensitivity affect detection. False-positive and false-negative results can occur. A positive screen is preliminary and requires an appropriate laboratory confirmation method. Results do not identify a medication brand, establish misuse, or prove current impairment.
Following instructions
Use the instructions for the exact product. Collection, activation, label removal, reading time, and the latest acceptable reading time can differ. A five-minute procedure for one cup should not be applied to every DOA test.
Ordering for your team?
Ask about Bulk and Wholesale Pricing and the panel options available for your program.
Shop MyDrugTestCups.com(423) 999-5399Email customer serviceReference sources
These resources explain general testing concepts and examples. They do not validate every listed drug against a MyDrugTestCups product.
- ARUP: estimated urine detection windows
- Alverno Laboratories: drug and urine detection reference
- Abbott Toxicology: testing and abbreviations
- AAFP: urine drug tests and interpretation
- SAMHSA: urine drug testing reference
- Rapid Response: drug-testing matrix
- AllTest: specialty substance-testing formats